临床试验/NCT03532711

NCT03532711已完成不适用

A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting

Fudan University0 个研究点目标入组 264 人开始时间: 2012年1月1日最近更新: 2018年5月22日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Fudan University
入组人数: 264
主要终点: Objective Response Rate (ORR)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers. It may also help doctors predict how patients will respond to treatment. In this study, we aimed to evaluate biomarkers in chemotherapy regimens for first-line chemotherapy for mCRC.

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

Chemotherapy

FOLFOX/XELOX/FOLFIRI

干预措施: fluorouracil (Drug)

结局指标

主要结局

Objective Response Rate (ORR)

时间窗: 2 months

objective response rate

次要结局

Overall Survival (OS)(6 months)
Progression Free Survival (PFS)(6 months)

研究者

发起方

Fudan University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Wen Zhang

Fudan University

相似试验

已完成

1 期

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before ProstatectomyProstate Cancer

NCT02324998Cambridge University Hospitals NHS Foundation Trust20

Unknown

2 期

XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal CancerChemotherapyColorectal Neoplasms

NCT03511170Harbin Medical University66

Unknown

2 期

XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal CancerChemotherapyColorectal Neoplasms

NCT03511183Harbin Medical University66

Unknown

不适用

Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella TheoryColorectal Cancer Metastatic

NCT04525807Fudan University200

招募中

1/2 期

Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human antibody) versus trifluridine/tipiracil +/- bevacizumab plus placebo in metastatic colorectal cancer patients after failure of oxaliplatin, irinotecan, fluoropyrimidine

2024-517024-20-00Centr Georges Francois Leclerc190